후두경을 이용한 이중관 기관지 튜브 삽관 시 심혈관계 반응을 억제하는 Remifentanil의 적정 용량
- Author(s)
- 신형용; 서보병; 이용철; 김진모; 김애라; 장영호; 배정인; 홍지희; Hyoung Yong Shin; Bo Byoung Seo; Yong Cheol Lee; Jin Mo Kim; Ae Ra Kim; Young Ho Jang; Jung In Bae; Ji Hee Hong
- Keimyung Author(s)
- Lee, Yong Cheol; Kim, Jin Mo; Kim, Ae Ra; Jang, Young Ho; Bae, Jung In; Hong, Ji Hee
- Department
- Dept. of Anesthesiology & Pain Medicine (마취통증의학)
- Journal Title
- 대한마취과학회지
- Issued Date
- 2007
- Volume
- 53
- Issue
- 1
- Abstract
- Background: The purpose of the present study was to determine the optimal dose of bolus remifentanil to attenuate hemodynamic changes to laryngoscopic double-lumen endobronchial intubation.
Methods: A total of 80 ASA I or II patients requiring double-lumen endobronchial intubation were randomly assigned to receive normal saline (NS) or one of the three different doses (0.5μg/kg (group R0.5), 1.0μg/kg (group R1.0) or 2.0μg/kg (group R2.0)) of remifentanil. Study drugs for each group were administered over 30 seconds after induction of anesthesia with thiopental sodium and rocuronium. Laryngoscopic endobronchial intubation was carried out 90 seconds after the administration of study drug. Arterial blood pressure and heart rate were recorded at preanesthetic baseline, preintubation, postintubation, and every one minute during the initial 5 minute period after intubation.
Results: Mean arterial pressure at postintubation period increased significantly compared to baseline value in group NS, R0.5, and R1.0, but there were no significant changes in group R2.0. Heart rate showed significant increase in comparison to baseline value at every postintubation period in group NS, R0.5, R1.0, with no significant changes in group R2.0.
Conclusions: We suggest that 2.0μg/kg of remifentanil attenuate the hemodynamic changes to double-lumen endobronchial intubation without adverse effect. (Korean J Anesthesiol 2007; 53: 48~53) Key Words: endobronchial intubation, hemodynamic change, remifentanil.
- 공개 및 라이선스
-
- 파일 목록
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.